Lapatinib Articles
Briefs: Eddingpharm deal with GSK China for Tykerb; AEterna Zentaris and Ergomed link on AEZS-108
10 April 2013
BRIC countries' breast cancer market to see 8% annual growth to 2017
14 February 2013
75% of US oncologists prescribe Pfizer's Xalkori just 10 months after the drug's launch
21 June 2012
News briefs from breast cancer meeting
12 December 2011
Natco joins forces with Lupin to sell generic Tykerb; gets orphan status for cancer drug candidate
24 June 2011
Leading 20 cancer drugs to generates sales of $1 billion in Australia by 2018; says Datamonitor study
14 March 2010
Europe’s CHMP backs Sanofi Pasteur’s Humenza and GSK’s Votrient; gives opinions on other products
22 February 2010
US FDA clears new uses for two GlaxoSmithKline drugs; Tykerb and Lamictal; GSK set to announce 3,000 job cuts
1 February 2010
US FDA clears restart of Roche Ph III Avastin trials; other strong data presented at San Antonio meeting
14 December 2009
Targeted agents will drive gastric cancer drug market to nearly $1.5 billion in 2018
5 November 2009
GlaxoSmithKline beats forecasts with 3rd quarter2009 profits leaping 34%, despite generic competition
28 October 2009
UK’s NICE won’t fund GSK’s breast cancer drug Tyverb; USA’s CDC backs Cervarix and Merck & Co’s Gardasil for boys
22 October 2009
GSK files to expand Tyverb use in USA & EU
3 April 2009
GSK appeals UK's NICE refusal for Tyverb
30 March 2009
Dutch NGO's CT claims rebutted by GSK
16 February 2009
UPDATE: Dutch NGO's CT claims rebutted by GSK and AZ
16 February 2009
Highlights of first PDCO meeting of 2009
26 January 2009
Tyverk/Femara boost delay in progression
22 December 2008
Ph II study of ImClone's IMC-A12 starts enrolling patients
24 November 2008
UK volume price plan for GSK's Tyverb
11 August 2008
GSK consults with health care officials on pipeline
21 July 2008
GSK's Tyverb gets European approval
23 June 2008
GSK's Tykerb enters Ph III breast cancer trial
19 May 2008
Stock Commentary - Europe - week to May 5, 2008
12 May 2008
Addendum: GSK's Tyverb
21 April 2008
Australia's govt to view PBS concerns
21 April 2008
Stock Commentary - Europe - week to March 24, 2008
31 March 2008
Delay to EU approval of GSK
31 March 2008
UK's NICE asked to develop new clinical health guidance for DoH
18 February 2008
GSK another to cut back in France
11 February 2008
US new drug approvals hit 24-year low
14 January 2008
GSK's Tyverb gets nod from CHMP
24 December 2007
Stock Commentary - New York week to Sept 10, 2007
17 September 2007
Oncologists reluctant to switch to Tykerb
20 August 2007
Tykerb side effects are "manageable," study
13 August 2007
GSK's Tykerb shows potential in breast cancer
11 June 2007
GSK submits lapatinib NDA in Japan
9 April 2007
Clarification to FDA's Tykerb approval
26 March 2007
Stock Commentary - Europe - week to Mar 19
26 March 2007
GSK initiates Ph III trial of Tykerb
5 March 2007
GSK's Tykerb under EMEA review
16 October 2006
FDA to review Tykerb as breast cancer therapy
25 September 2006
GSK's Tykerb 'to rival Herceptin,' Ph III study
12 June 2006
GSK updates Paxil warnings
19 December 2005
Stock Commentary - Europe
23 May 2005
GlaxoSmithKline's R&D pipeline looks set to drive near-term growth
21 February 2005
Stock Commentary - Europe
8 November 2004
Showing 1-73 of 73 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
